


CDC India Opportunities Limited
Annual Report and Financial Statements
Year ended 31 December 2019

Company Number: 08523625



Contents

Directors' report	1
Directors' Responsibilities Statement	2
Independent Auditor's Report to the members CDC India Opportunities Limited	3
Statement of Financial Position	5
Statement of Comprehensive Expense	6
Statement of Cash Flows	7
Statement of Changes in Equity	8
Notes to the Accounts	9

Directors' report

The Directors are pleased to present their report together with the audited financial statements of the Company for the period ended 31 December 2019.

Directors

Colin Buckley

Jane Earl

Clive MacTavish

Appointed 10 September 2019

Appointed 19 June 2017

Appointed 28 April 2016, resigned 9 September 2019

The Company's articles of association provide that one third of the Directors retire by rotation at each annual general meeting. The Director retiring by rotation at the forthcoming annual general meeting is Clive MacTavish. Being eligible, Clive MacTavish offers himself for re-election.

Principal activity

The principal activity of the Company is that of an investment company, investing in emerging markets.

Business and performance review

The Company recorded a net loss of US\$6,839,107 for the year ended 31 December 2019 (2018: net loss US\$8,494,498). The net liability value of the Company was US\$3,239,210 at 31 December 2019 (2018: net asset US\$3,599,895).

Financial statements

The Statement of Directors' Responsibilities is shown separately. The Company has taken advantage of section 414B of the Companies Act 2006 not to produce a strategic report on the grounds that it is a small company. Notes 13 and 14 to the financial statements includes the Company's policies and processes for managing its financial risk, details of its financial instruments and hedging activities and its exposures to credit and liquidity risk. The Directors believe that the Company is well placed to manage its business risks successfully.

Principal risks

The Company invests in developing countries. The Company values its portfolio according to the valuation methodology described in note 16 to the accounts. Investments are valued at fair value, which is the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date.

Valuation risks are mitigated by comprehensive reviews of the application of the valuation methodology.

Going Concern

The Directors have a reasonable expectation that the Company has adequate financial resources to continue in operational existence for the next 12 months. There is a loan agreement in place with its parent, CDC Group plc which is repayable on demand. The Directors have considered the Company's position and note that current assets are less than the current liabilities even when excluding the inter-company payables and therefore relies on CDC Group plc to cover any ongoing expenses. These conditions indicate there is a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.

CDC Group plc has issued a letter of support which confirms that CDC Group plc will only request repayment of the loan provided that the Company has sufficient liquid resources to do so. Further to this, the letter of support also confirms that CDC Group plc will cover any ongoing expenses incurred by the Company. Whilst the letter of support is not a legal contract, the Directors have full confidence that CDC Group plc will continue to support the Company. The Directors have considered the impact of Brexit and have concluded there will be no material impact on the Company. Following the year-end the Board has reviewed and evaluated the impact of Covid-19 to ensure that no going concern issues have arisen. Refer to note 18 for further information.

Subsequent events

There have been no material events since the reporting period that would require adjustment to these financial statements, refer to note 18 for detailed note.


Other information

So far as each Director is aware at the date of approval of this report, there is no relevant audit information of which the Company's auditor is unaware and each Director confirms that he or she has taken all the steps that he or she ought to have taken as a Director in order to make himself or herself aware of any relevant audit information and to establish that the Company's auditor is aware of that information. Each Director benefits from an indemnity which includes provisions in relation to duties as a Director of the Company or an associated company and protection against derivative actions.

Appointment of auditor

In accordance with Section 489 of the Companies Act 2006, a resolution proposing the continuing appointment of Deloitte LLP as the Company's auditor will be put the members of the Company, following which, in accordance with Section 487, Deloitte will be deemed to be reappointed and will therefore continue in office for the following year.

Approved by the Board of directors on 25 September 2020 and signed on behalf of the Board on 25 September 2020



Jane Earl

Director and Company Secretary

Directors' Responsibilities Statement

The Directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the financial statements in accordance with International Financial Reporting Standards (IFRSs) as adopted by the European Union. Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, International Accounting Standard 1 requires that Directors:

- properly select and apply accounting policies;
- present information, including accounting policies, in a manner that provides relevant, reliable, comparable and understandable information;
- provide additional disclosures when compliance with the specific requirements in IFRSs are insufficient to enable users to understand the impact of particular transactions, other events and conditions on the entity's financial position and financial performance; and
- make an assessment of the company's ability to continue as a going concern.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Independent Auditor's Report to the members of CDC India Opportunities Limited

Report on the audit of the financial statements

Opinion

In our opinion the financial statements of CDC India Opportunities Limited (the 'company'):

- give a true and fair view of the state of the company's affairs as at 31 December and of its loss for the year then ended;
- have been properly prepared in accordance with International Financial Reporting Standards (IFRSs) as adopted by the European Union; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements which comprise:

- the statement of financial position;
- the statement of comprehensive expense;
- the statement of cash flows;
- the statement of changes in equity; and
- the related notes 1 to 18.

The financial reporting framework that has been applied in their preparation is applicable law and IFRSs as adopted by the European Union.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the Financial Reporting Council's (the 'FRC's') Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material uncertainty related to going concern

We draw attention to note 1 in the financial statements, which indicates that the Company relies on CDC Group plc to cover ongoing expenses. A letter of support has been received from CDC Group plc but this is not legally binding. As stated in note 1, these events or conditions, along with the other matters as set forth in note 1 to the financial statements, indicate that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual accounts, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in respect of these matters.

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Independent Auditor's Report to the members CDC India Opportunities Limited

Report on other legal and regulatory requirements

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report have been prepared in accordance with applicable legal requirements.

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the directors' report.

Matters on which we are required to report by exception


Under the Companies Act 2006 we are required to report in respect of the following matters if, in our opinion:

- the directors were not entitled to take advantage of the small companies' exemption from the requirement to prepare a strategic report;
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

We have nothing to report in respect of these matters.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Ghorzang Aziz (Senior Statutory Auditor)

For and on behalf of Deloitte LLP

Statutory Auditor

London

United Kingdom

28 September 2020

Statement of Financial Position


As at 31 December

	Notes	31 December 2019 US\$	31 December 2018 US\$
Assets			
Non-current assets			
Equity investments	2	63,863,496	63,339,067
Deferred tax asset		-	-
		63,863,496	63,339,067
Current assets			
Cash and cash equivalents	3	231,834	158,290
Forward foreign exchange contracts	5	-	-
Other receivables		351	-
		232,185	158,290
Total assets		64,095,681	63,497,357
Equity and liabilities			
Shareholders' equity			
Issued capital	4	17,736,000	17,736,000
Accumulated deficit		(20,975,212)	(14,136,105)
		(3,239,212)	3,599,895
Non-current liabilities			
Deferred tax liability	7	2,723,370	1,876,236
Forward foreign exchange contracts	5	-	-
		2,723,370	1,876,236
Current liabilities			
Amounts due to parent company	10	64,344,445	53,660,236
Forward foreign exchange contracts	5	247,196	4,350,649
Other payables	11	19,882	10,341
		64,611,523	58,021,226
Total liabilities		67,334,893	59,897,462
Total equity and liabilities		64,095,681	63,497,357

The Company registration number is 08523625.

The accompanying notes form part of the financial statements.

The accounts were approved by the members of the Board on 25 September 2020 and were signed on their behalf by:



Jane Earl
Director and Company Secretary

Registered in England No 03830175

Statement of Comprehensive Expense

For the 12 months to 31 December

	Notes	2019 Total US\$	2018 Total US\$
Investment income		131,923	73,500
Fair value gains/(losses)	2	524,430	(4,485,583)
Administration fee		(1,266,781)	(1,613,428)
Administrative and other expenses	8	(20,170)	- (16,256)
Expense from operations before tax and finance costs		(762,521)	(6,115,267)
Finance costs	9	(4,239,171)	(4,239,171)
Net foreign exchange differences	6	(1,122,204)	2,232,875
Expense from operations before tax		(5,991,973)	(8,048,063)
Income tax expense	7	(847,134)	(446,435)
Total comprehensive expense for the year		(6,839,107)	(8,494,498)

The accompanying notes form part of the financial statements.

All the above items are derived from continuing operations.

The company has no items of other comprehensive expense for the current or previous year.

Statement of Cash Flows

For the 12 months to 31 December

	Notes	2019 US\$	2018 US\$
Cash flows from operating activities			
Expense from operations before tax		(5,991,973)	(8,048,063)
Change in value of equity investments	2	(524,430)	4,485,583
Foreign exchange movements		96	331
Income/(Expense) from operations before changes in working capital		(6,516,307)	(3,562,149)
Change in amounts due to parent company		6,445,038	(3,280,840)
Change in other receivables		(352)	-
Change in other payables		9,543	(450)
Change in derivative financial instruments		(4,103,453)	2,708,116
Cash flows from operating activities		(4,165,531)	(4,135,323)
Cash flows from investing activities			
Acquisition of equity investments		-	-
Cash flows from investing activities		-	-
Cash flows from financing activities			
Loan interest & commitment fees		4,239,171	4,239,171
Issue of share capital	4	-	-
Cash flows from financing activities		4,239,171	4,239,171
Net increase in cash and cash equivalents		73,640	103,848
Cash and cash equivalents at 1 January		158,290	54,773
Effect of exchange rate fluctuations on cash held		(96)	(331)
Cash and cash equivalents at 31 December		213,834	158,290

The accompanying notes form part of the financial statements.

Statement of Changes in Equity

	Share capital US\$	Retained earnings/ (Accumulated deficit) US\$	Total US\$
At 1 January 2018	17,736,000	(5,641,607)	12,094,393
Changes in equity for 2018			
Total comprehensive expense for the year	-	(8,494,498)	(8,494,498)
At 31 December 2018	17,736,000	(14,136,105)	3,599,895
Changes in equity for 2019			
Total comprehensive expense for the year	-	(6,839,107)	(6,839,107)
At 31 December 2019	17,736,000	(20,975,212)	(3,239,212)

The accompanying notes form part of the financial statements.

Notes to the Accounts

Continued

1. Corporate information and accounts preparation

Corporate information

The financial statements of CDC India Opportunities Limited (the Company) for the year ended 31 December 2019 were authorised for issue in accordance with a resolution of the Directors on 25 September 2020. CDC India Opportunities Limited is a limited company incorporated in England and Wales, limited by shares. It is a wholly owned subsidiary of CDC Group plc, a public limited company incorporated in England and Wales. The Company's registered office is located at Level 1, 123 Victoria Street, London SW1E 6DE, England. CDC Group plc acts as the intermediate parent company of the Company and its financial statements are publicly available.

The ultimate parent of the Company at the year end was the Secretary of State for International Development. Following the merger of the Department for International Development and the Foreign and Commonwealth Office in September 2020, the ultimate parent of the Company will become the Secretary of State for Foreign, Commonwealth and Development Affairs. It is anticipated that this change will take legal effect on 30 September 2020.

The principal activity of the Company is that of an investment company.

Statement of compliance

The financial statements of the Company have been prepared in accordance with International Financial Reporting Standards (IFRS) and its interpretations adopted by the International Accounting Standards Board (IASB) and as adopted by the EU.

Basis of preparation

The financial statements have been prepared on a historical cost basis, except for derivative financial instruments and other financial instruments that have been presented and measured at fair value in accordance with relevant accounting standards.

The financial statements are presented US dollars, which is also the Company's functional currency. Assets and liabilities are retranslated at spot rates at the statement of financial position date. Foreign exchange gains and losses resulting from the settlement of such transactions and from translation of assets and liabilities denominated in foreign currencies at the yearend exchange rate are recognised in the statement of comprehensive income.

The preparation of financial statements under IFRS requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected. Refer to note 2 for sensitivity analysis.

A summary of other significant accounting policies can be found in note 16.

In 2018, CDC has applied IFRS 9 Financial Instruments for the first time. The nature and effect of the changes as a result of adoption of this new accounting standards are described in note 17.

Going concern

Notwithstanding net current liabilities of US\$64,379,338 as at 31 December 2019 and a loss for the year then ended of US\$6,839,107, the financial statements have been prepared on a going concern basis which the Directors consider to be appropriate for the following reasons.

The Directors have a reasonable expectation that the Company has adequate financial resources to continue in operational existence for the next 12 months. There is a loan agreement in place with its parent, CDC Group plc which is repayable on demand. The Directors have considered the Company's position and note that current assets are less than the current liabilities even when excluding the inter-company payables and therefore relies on CDC Group plc to cover any ongoing expenses. These conditions indicate there is a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business.

CDC Group plc has issued a letter of support which confirms that CDC Group plc will only request repayment of the loan provided that the Company has sufficient liquid resources to do so. Further to this, the letter of support also confirms that CDC Group plc will cover any ongoing expenses incurred by the Company. Whilst the letter of support is not a legal contract, the Directors have full confidence that CDC Group plc will continue to support the Company. The Directors have considered the impact of Brexit and have concluded there will be no material impact on the Company. Following the year-end the Board has reviewed and evaluated the impact of Covid-19 to ensure that no going concern issues have arisen. Refer to note 18 for further information.

Notes to the Accounts

Continued

2. Equity investments

	2019 Listed Shares US\$	2019 Unlisted Shares US\$	2019 Total US\$	2018 Listed Shares US\$	2018 Unlisted Shares US\$	2018 Total US\$
At 1 January, at fair value	12,224,049	51,115,018	63,339,067	20,377,818	47,446,832	67,824,650
Additions	-	-	-	-	-	-
Disposals	-	-	-	-	-	-
Transfers	-	-	-	-	-	-
Increase/(decrease) in fair value for the year	6,604,988	(6,080,558)	524,430	(8,153,769)	3,668,186	(4,485,583)
At 31 December, at fair value	18,829,037	45,034,460	63,863,497	12,224,049	51,115,018	63,339,067

Listed shares represent Level 1 of the fair value hierarchy. Unlisted shares are included within Level 3 of the fair value hierarchy. The Company holds no Level 2 investments. There have been nil (2018: nil) transfers from Level 3 (unlisted shares) to Level 1 (listed shares) during the year.

The different levels have been defined as follows:

Level 1: quoted prices (unadjusted) in active markets for identical assets.

Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: inputs for the asset that are not based on observable market data (unobservable inputs).

The Company's fair value methodology for equity investments is disclosed in note 16.

Investments classified within Level 3 have significant unobservable inputs, as they trade infrequently. As observable prices are not available for these securities, the Company has used valuation techniques to derive the fair value.

Level 3 valuations are reviewed on a quarterly basis by the valuation committee who report to the Board of Directors on a quarterly basis. The committee considers the appropriateness of the valuation model inputs, as well as the valuation results, using various valuation methods and techniques generally recognised as standard within the industry.

Level 3 equity investments amount to US\$45,034,460 and consist of private equity positions. Direct equity investments which are valued based on unobservable inputs are included in Level 3. The valuation techniques that require significant unobservable inputs are the comparable trading multiples.

Trading Multiples

US\$45,034,460 of the Company's portfolio is valued using comparable trading multiples. Management determines comparable public companies (peers) based on industry, size, developmental stage and strategy. Management then calculates a trading multiple for each comparable company identified. The multiple is calculated by dividing the enterprise value of the comparable company by either its earnings before interest, taxes, depreciation and amortisation (EBITDA) or book value. The trading multiple is then discounted for considerations such as illiquidity and differences between the comparable companies based on company-specific facts and circumstances.

Description	Fair value at 31 Dec 2019 US\$m	Valuation Technique	Unobservable Inputs	Weighted average input	Reasonable possible shift +/- (absolute value)	Change in Valuation US\$m
Global Equity Securities	45.0	Comparable trading multiples	EBITDA multiple	15.5	10%	4.0
			Discount to multiple	10%	10%	5.1

The fair value hierarchy also applies to forward foreign exchange contracts, see note 5 for further details.

3. Cash and cash equivalents

	2019 US\$	2018 US\$
Cash at bank and in hand	231,834	158,290
Total cash and cash equivalents	231,834	158,290

Cash at bank and in hand earns no interest. The fair value of cash and cash equivalents is US\$231,834 (2018: US\$158,290).

Notes to the Accounts

Continued

4. Issued capital

	2019 No. of shares	2018 No. of shares
Authorised		
Ordinary shares of US\$1 each	16,000	16,000
Class A ordinary shares of US\$10,000 each.	3,000	3,000

	2019 No. of shares	2019 US\$	2018 No. of shares	2018 US\$
Allotted, called up and fully paid Class A Ordinary shares				
At 1 January, Ordinary shares of US\$10,000 each	1,772	17,720,000	1,772	17,720,000
Issued Ordinary shares of US\$10,000 each	-	-	-	-
At 31 December, Ordinary shares of US\$10,000 each	1,772	17,720,000	1,772	17,720,000

	2019 No. of shares	2019 US\$	2018 No. of shares	2018 US\$
Allotted, called up and fully paid ordinary shares				
At 1 January, ordinary shares of US\$1 each	16,000	16,000	16,000	16,000
Issued ordinary shares of US\$1 each	-	-	-	-
At 31 December, ordinary shares of US\$1 each	16,000	16,000	16,000	16,000

5. Forward foreign exchange contracts ('FFEC')

Forward foreign exchange contracts (non-current) with parent company comprises:

	2019 US\$	2018 US\$
Gross foreign exchange contracts in profit	-	-
Gross foreign exchange contracts in loss	(247,196)	(4,350,649)
Total forward foreign exchange contracts	(247,196)	(4,350,649)

In the statement of financial position, these are analysed as follows:

	2019 US\$	2018 US\$
Current assets	-	-
Current liabilities	(247,196)	(4,350,649)
Total forward foreign exchange contracts	(247,196)	(4,350,649)

In accordance with the fair value hierarchy described in note 2, forward foreign exchange contracts are measured using Level 2 inputs.

The Company's US Dollar denominated contracts with parent company comprise:

	2019 Foreign currency in millions	2019 Average spot price	2019 US\$	2018 Foreign currency in millions	2018 Average spot price	2018 US\$
Foreign currency						
Indian rupee	4,358.0	71.13333	61,265,230	6,403.0	72.69833	88,076,297

Gains or losses arising from the movement in fair value of this FFEC are taken to the statement of comprehensive income.

6. Net foreign exchange differences

	2019 US\$	2018 US\$
Exchange (losses)/gains arising on forward foreign exchange contracts	(1,121,942)	2,233,206
Exchange losses arising on cash and cash equivalents	(96)	(331)
Other exchange differences	(166)	-
Total net foreign exchange differences	(1,122,204)	2,232,875

Notes to the Accounts

Continued

7. Income tax expense

	2019 US\$	2018 US\$
Current year charge	577,833	446,435
Overseas deferred tax charge	269,301	-
Total income tax expense per the statement of comprehensive income	847,134	446,435

The UK Corporation tax rate is reconciled to the effective tax rate for the year as follows:

	2019 %	2018 %
UK Corporation rate	19.0	19.0
Effect of current year losses for which no deferred tax assets has been recognised	-	-
Non-taxable fair value adjustment	(19.3)	(10.6)
Effect of overseas taxation	(4.5)	(5.5)
Effect of non-taxable dividends	0.4	0.2
Effect of non-deductible expenses	(4.0)	(3.8)
Effect of UK transfer pricing adjustment	(10.0)	(7.4)
Effect of prior year unrecognised losses	-	2.6
Effect of reversal of prior year unrecognised deductible temporary differences	11.3	-
Recognised losses	(7.1)	-
Effective tax rate for the year	(14.1)	(5.5)

8. Administrative and other expenses

	2019 US\$	2018 US\$
Auditor remuneration	10,619	10,324
Other expenses	9,551	5,932
Total administrative and other expenses	20,170	16,256

Audit remuneration is for the statutory audit of financial statements. The Company has no employees and no related staff costs. Directors did not receive emoluments in respect of services for this company.

9. Finance costs

	2019 US\$	2018 US\$
Loan interest payable to CDC Group plc	4,195,472	4,195,472
Loan commitment fee payable to CDC Group plc	43,699	43,699
Total finance costs	4,239,171	4,239,171

10. Amounts due to parent company

	2019 US\$	2018 US\$
Loan due to CDC Group plc	41,380,000	41,380,000
Current account payable to CDC Group plc	10,152,663	3,707,625
Loan interest and commitment fees due to CDC Group plc	12,811,782	8,572,611
Total amounts due to parent company	64,344,445	53,660,236

Included in the amounts due to the parent company was an inter-group loan of US\$41,380,000 (2018: US\$41,380,000) which attracts a 10% interest rate charge due semi-annually to the parent company. The total size of the inter-group loan facility is US\$50,000,000 (2018: US\$50,000,000).

Notes to the Accounts

Continued

11. Other payables

	2019 US\$	2018 US\$
Auditor remuneration	10,595	10,341
Other payables	9,287	-
Total other payables	19,882	10,341

Audit remuneration is for the statutory audit of financial statements.

12. Related party transactions

During the year, the Company entered into transactions with its parent company, all of which were carried out on an arm's length basis.

The transactions entered into and trading balances outstanding at 31 December were as follows:

	2019 US\$	2018 US\$
Statement of comprehensive income		
Finance cost	(4,239,171)	(4,239,171)
Administration fee	(1,266,781)	(1,613,428)
Statement of financial position		
Forward foreign exchange contracts	(247,196)	(4,350,649)
Amounts due to parent company	(64,344,445)	(53,660,236)

Included in the amounts due to the parent company was an inter-group loan of US\$41,380,000 (2018: US\$41,380,000) which attracts a 10% interest rate charge due semi-annually to the parent company. The total size of the inter-group loan facility is US\$50,000,000 (2018: US\$50,000,000).

13. Financial instruments

The Company's principal financial assets (as defined in IFRS 7) comprise cash, equity investments and foreign exchange contracts. For the purposes of this note, the disclosure on financial assets has been split between these asset classes in order to give more meaningful information. Financial liabilities comprise amounts due to parent company and foreign exchange contracts.

Interest rate exposures

	Fixed rate US\$	Floating rate US\$	No interest US\$	Total US\$	Fixed rate weighted average interest rate %	Fixed rate weighted period to full maturity Years	No interest maximum period to full maturity Years
Financial assets: Cash							
2019	-	-	231,834	231,834	-	-	-
2018	-	-	158,290	158,290	-	-	-

Currency exposures

The tables below show the Company's currency exposures that give rise to exchange rate gains and losses that are recognised in the statement of comprehensive income. Such exposures comprise those monetary assets and liabilities that are not denominated in the Company's functional currency. In order to protect the Company's US dollar statement of financial position and reduce cash flow risk, the Company uses forward foreign exchange contracts to hedge foreign exposures.

The following table shows the Company's foreign currency denominated cash balances:

Functional currency	2019 US\$	2018 US\$
Indian rupee	4,242	4,352
Total	4,242	4,352

Notes to the Accounts

Continued

13. Financial instruments (continued)

The following table shows the functional currency of the Company's equity investments:

Functional currency	2019 Listed Shares US\$	2019 Unlisted Shares US\$	2018 Listed Shares US\$	2018 Unlisted Shares US\$
Indian rupee	18,829,037	45,034,460	12,224,049	51,115,018
Total	18,829,037	45,034,460	12,224,049	51,115,018

Liquidity risk

The following tables show the maturity profile of the Company's financial assets and liabilities other than cash and equity investments:

Financial assets: Maturity profile	2019 Forward foreign exchange contract US\$	2018 Forward foreign exchange contract US\$
Due within one year	-	-
Due within two to three years	-	-
Total	-	-

Financial liabilities: Maturity profile	2019 Forward foreign exchange contract US\$	2019 Amounts owed to parent company US\$
Due within one year	247,196	64,344,445
Due between two and five years	-	-
Total	247,196	64,344,445

Financial liabilities: Maturity profile	2018 Forward foreign exchange contract US\$	2018 Amounts owed to parent company US\$
Due within one year	4,350,649	53,660,236
Due between two and five years	-	-
Total	4,350,649	53,660,236

The Company does not net off contractual amounts of financial assets and liabilities.

Fair value of financial assets and liabilities

Financial assets

Unquoted equity investments are included in the statement of financial position at fair value. There is no material difference between the fair value and the book value of the Company's cash.

Financial liabilities

There is no material difference between the fair value and the book value of the Company's amounts payable to parent company. The Company's foreign exchange contracts in loss is held in the statement of financial position at fair value.

Notes to the Accounts

Continued

14. Financial risk management

The Company's activities expose them to a variety of financial risks including market risk, credit risk, liquidity risk and cash flow interest rate risk. Market risk includes foreign currency risk, interest rate risk and price risk. The main financial risks managed by the Company are foreign currency risk, interest rate risk, liquidity risk and credit risk. The Company use forward foreign exchange contracts, to manage their financial risks associated with their underlying business activities and the financing of those activities. The Company do not undertake any trading activity in financial instruments.

Liquidity risk

The Company's policy on liquidity risk is to ensure that they always have sufficient funding to meet all short to medium-term funding requirements. The Company's cash balance at 31 December 2019 was US\$231,834 (2018: US\$158,290) and its capital commitments including long-term commitments were nil (2018: nil).

The Company's contractual maturity of the forward foreign exchange contracts is disclosed in note 13 Financial instruments.

Credit risk

Credit risk is the risk of financial loss to the Company if the counterparty to a financial instrument fails to meet its contractual obligations. The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk as at 31 December was:

	Notes	2019 US\$	2018 US\$
Equity investments	2	63,863,496	63,339,067
Cash and cash equivalents	3	231,834	158,290
Total		64,095,330	63,497,357

The Company's policy is to recognise an impairment loss when objective evidence exists that the estimated future cash flows of the asset have decreased and that this decrease can be reliably estimated. Several factors are considered when identifying indicators of impairment including breach of contract or financial difficulties being experienced by the obligor. Based on historical trends the Company believes no impairment allowance is necessary in respect of financial assets not past due.

Credit risk on the Company's cash balances and FFECs is mitigated as the Company transact with institutions with high credit ratings. If possible, cash is deposited with financial institutions that have a long-term credit rating ascribed by Moody's of A2 or above.

Market risk

Foreign currency risk

Exposure to currency risk arises in the normal course of the Company's investment business. The Company has exposure to the Indian rupee. As at 31 December 2019 and 2018, all equity investments held by the Company, were denominated in Indian rupee. In addition, the Company has a cash balance of US\$4,242 as at 31 December 2019 (2018: US\$4,352) denominated in Indian rupee. In order to protect the Company's US dollar statement of financial position and reduce cash flow risk, the Company uses forward foreign exchange contracts to hedge foreign exposures.

In preparing the sensitivity analysis a movement of 10% has been used as it represents a reasonable and realistic potential change in value. The sensitivity analysis is based on the assumption that all other variables remain constant, a 10% movement in the average exchange rate for the Indian rupee against US dollar with all other variables held constant would impact loss by US\$6,386,774 (2018: 10% movement, impact loss: US\$3,184,241).

Equity price risk

Equity investment are valued in accordance with CDC valuation methodology and included in the financial statements at fair value, with gains and losses being taken to the statement of comprehensive income.

A 10% change in the fair value of the Company's equity investment would impact the Company's loss by US\$6,386,350 (2018: 10% change, impact loss US\$6,333,907).

Valuation risk

The Company values its portfolio according to CDC valuation methodology. CDC valuation guidelines have been developed in accordance with the International Private Equity and Venture Capital Valuation Guidelines. Investments are valued at fair value, which is the price that would be received to sell an asset in an orderly transaction between market participants given current market conditions at the measurement date. The detailed valuation methodology sets out best practice with respect to valuing investments. Valuation risks are mitigated by comprehensive reviews of underlying investments in the private equity funds and direct investments carried out by the managers of the private equity funds at least twice a year. These valuations are reviewed by CDC management and then considered by the Audit, Compliance and Risk Committee. The details of the valuation methodology are given in note 14 to the accounts under the Investments heading.

Notes to the Accounts

Continued

14. Financial risk management (continued)

Capital management

CDC considers its capital to be the total equity shown in statement of changes of equity. The Company's objectives when managing capital are:

- to safeguard the Company's ability to continue as a going concern, so that it can continue to provide returns and benefits for stakeholders; and
- to maintain a strong capital base to support the development of the Company's businesses.

The Board monitors the results of the Company and its financial position.

15. Capital commitments and contingencies

Amounts contracted for but not provided for in the accounts amounted to nil (2018: nil) for investment commitments (see note 14).

There are no contingencies as at the reporting date (2018: nil).

16. Summary of significant accounting policies

Non-current assets

Investments

The Company classifies their equity investments as financial assets at fair value through profit and loss. Management determines the classification of its investments at initial recognition. Apart from loans and receivables, financial instruments are designated as fair value through profit and loss because the fair value of the investment portfolio is a key performance indicator for the Company.

Financial assets at fair value through profit and loss

These financial assets are designated as assets held at fair value through profit and loss by management at the date of inception. FFECs are also classified as held for trading in this category unless they are designated as hedges. Assets in this category are classified as current assets if they are either held for trading or are expected to be realised within 12 months of the statement of financial position date.

The Company's fair value methodology has been derived using the International Private Equity and Venture Capital Valuation Guidelines. This methodology is applied to direct investments and investments held within funds. The approach to calculating the fair value is as follows:

- the enterprise value is determined for the investee company or fund using a methodology that is appropriate in light of the nature, facts and circumstances of the investment and its materiality in the context of the total investment portfolio using reasonable assumptions and estimates;
- the enterprise value is adjusted for surplus assets or liabilities or any other relevant factor;
- higher ranking financial instruments are deducted taking into account any financial structuring that may dilute the investment holding;
- the net attributable enterprise value is apportioned between the financial instruments held according to their ranking; and
- the amounts derived are allocated according to the holding in each financial instrument, representing their fair value.

Valuation methodologies used are as follows:

- investments where fair value derives mainly from the underlying assets, such as funds managed by fund managers, are valued at net asset value using appropriate valuation measures for the underlying assets and liabilities;
- quoted equity is normally valued at the quoted share price. However, in certain circumstances the quoted price may be considered to not represent fair value for example: shares are closely held by related parties; the shares are very thinly traded and small trades lead to excessive volatility in quoted price; or substantial transactions occur at a price that is not the quoted price. Where this is considered the situation an appropriate alternative methodology is used;
- realisations in process are valued at the expected realisation proceeds, although discounts are applied to reflect the level of certainty of the transaction completion;
- if there has been a recent investment in the company, the price of the recent investment, less any impairment charge, is used to determine fair value;
- early stage companies without positive cash flow or profit are valued using an appropriate industry benchmark if that gives a reliable estimate of fair value;
- companies with maintainable profits or cash flows are valued on an earnings basis using an appropriate earnings multiple from companies in similar sectors and markets;

Notes to the Accounts

Continued

16. Summary of significant accounting policies (continued)

- companies in industries with specific valuation metrics are valued using those specific valuation metrics where they provide the most reliable estimate of fair value;
- companies with no maintainable profits or cash flows at present, but whose cash flows can be forecast with confidence, are valued using future cash flows discounted at the appropriate risk-adjusted discount rate; and
- in exceptional cases, where fair value cannot be reliably measured, the investment is valued at the previous carrying value unless there is evidence of value impairment, in which case value is reduced to reflect the extent of estimated impairment.

Gains and losses realised on disposal or redemption, by reference to the valuation at the previous statement of financial position date and unrealised gains and losses from changes in the fair values of the equity portfolio are taken to the statement of comprehensive income.

The Company uses settlement date accounting when accounting for regular purchases or sales. When the Company becomes party to a sales contract of an equity investment, it de-recognises the asset on the day ownership is transferred. Any gains or losses arising on purchases between trade and settlement date are accounted for in the statement of comprehensive income.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. These arise either when the Company provides money to a counterparty in the form of loans with no intention of trading it, or, in the case of trade receivables and note receivables, in the normal course of business.

Loans are recognised at amortised cost; initially, this is measured as the fair value of the cash given to originate the loan. They are subsequently measured at amortised cost using the effective interest method. Maturities greater than 12 months are included in non-current assets with the remainder in current assets. Gains or losses are recognised in the statement of comprehensive income when the loan is de-recognised or impaired, as well as through the amortisation process. Where there is objective evidence that a loan's carrying value exceeds the present value of the discounted future cash flows expected to be generated from the asset, the loan is deemed to be impaired and the carrying value reduced accordingly, with the loss recognised in the statement of comprehensive income.

Forward foreign exchange contracts ('FFECs')

The Company use FFECs as part of their asset management activities to manage exposures to foreign currency risk. The Company does not use FFECs for speculative purposes.

Gains and losses on FFECs transacted as economic hedges but not qualifying for hedge accounting are taken to the statement of comprehensive income.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank. Cash equivalents are short term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value.

Impairment of assets

IFRS 9's impairment requirements use more forward-looking information to recognise expected credit losses – the 'expected credit loss (ECL) model'. This replaces IAS 39's 'incurred loss model'. Instruments within the scope of the new requirements include loans and other debt-type financial assets measured at amortised cost and FVOCI, trade receivables, contract assets recognised and measured under IFRS 15 and loan commitments and some financial guarantee contracts (for the issuer) that are not measured at fair value through profit or loss.

Recognition of credit losses is no longer dependent on the Company first identifying a credit loss event. Instead the Company considers a broader range of information when assessing credit risk and measuring expected credit losses, including past events, current conditions, reasonable and supportable forecasts that affect the expected collectability of the future cash flows of the instrument.

In applying this forward-looking approach, a distinction is made between:

- financial instruments that have not deteriorated significantly in credit quality since initial recognition or that have low credit risk ('Stage 1') and;
- financial instruments that have deteriorated significantly in credit quality since initial recognition and whose credit risk is not low ('Stage 2').

'Stage 3' would cover financial assets that have objective evidence of impairment at the reporting date.

A '12-month expected credit loss' is recognised for the first category while 'lifetime expected credit losses' are recognised for the second category.

Notes to the Accounts

Continued

16. Summary of significant accounting policies (continued)

Measurement of the expected credit losses is determined by a probability-weighted estimate of credit losses over the expected life of the financial instrument.

The carrying amounts of assets and financial instruments are reviewed at each statement of financial position date to determine whether there is any indication of impairment.

If any such indication exists, the recoverable amount of the asset is estimated. An impairment loss is recognised whenever the carrying amount of an asset or its cash-generating unit exceeds its recoverable amount. Impairment losses are recognised in the statement of comprehensive income.

The recoverable amount of the Company's assets is the greater of their fair value less costs to sell and value in use, calculated as the present value of expected future cash flows. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash-generating unit to which the asset belongs.

An impairment loss in respect of all assets is reversed if a subsequent increase in recoverable amount can be related objectively to an event occurring after the impairment loss was recognised or if there has been a change in the estimates used to calculate the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

Financial liabilities

Financial liabilities are initially measured at fair value less any directly attributable transaction costs. Subsequent to initial recognition, contractual obligations, excluding FFECs, to deliver cash or another financial asset to another entity are measured at amortised cost using the effective interest method.

Provisions, contingent liabilities and contingent assets

Provisions are recognised if there is a present obligation, whether legal or constructive, which has arisen as a result of a past event; it is probable that an outflow of resources will be required to settle the obligation; and a reliable estimate can be made of the amount of the obligation.

Contingent liabilities are disclosed where the existence of an obligation will only be confirmed by future events or where the amount of the obligation cannot be measured with reasonable reliability.

Contingent assets are not recognised, but are disclosed where an inflow of economic benefits is probable.

Income

Income is recognised to the extent that it is probable that the economic benefits will flow to the Company and can be reliably measured. Interest is recognised as earned on an accruals basis, but is excluded if it becomes more than ninety days overdue. Investment income is accounted for on an accruals basis unless collectability is in doubt.

Income tax

Current tax is recognised as income or expense and is included in the net profit for the year, unless it relates to a transaction or event which is recognised directly in equity, whereupon the current tax is charged or credited to equity accordingly.

Current and deferred tax assets and liabilities are offset only when they arise from the same tax reporting Company and relate to the same tax authority and when the legal right to offset exists.

Current and deferred taxes are recognised as a tax credit or expense in the year in which they arise except for deferred taxes recognised or disposed of upon the acquisition or disposal of a subsidiary.

Deferred tax is provided in full using the liability method on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the Company financial statements. Deferred tax is measured on an undiscounted basis at the tax rates that are expected to apply in the periods in which temporary differences reverse, based on tax rates and laws enacted or substantially enacted at the statement of financial position date.

Deferred tax assets are recognised only to the extent that the Directors consider that it is probable that there will be suitable taxable profits from which the future reversal of the underlying temporary differences can be deducted.

Non-UK withholding tax is calculated on investment income (currently classified as fair value gains) which is due on investments held outside the UK.

Critical accounting judgments

The preparation of financial statements in accordance with IFRS requires management to exercise judgment in applying relevant accounting policies. The key areas involving a higher degree of judgment or complexity, or areas where assumptions are significant to the individual financial statements, is the application of the going concern assumption and the fair value of financial assets.

Notes to the Accounts

Continued

16. Summary of significant accounting policies (continued)

Sources of estimation uncertainty

The preparation of financial statements in accordance with IFRS requires the use of estimates. The key accounting estimates are the carrying value of our equity investments, which are stated at fair value. Asset valuations for unquoted investments are inherently subjective, as they are made on the basis of assumptions which may not prove to be accurate such as discount rates and assumptions in expected cash flows. A sensitivity analysis is provided in note 2.

IFRSs issued but not yet effective

The accounting policies set out in these financial statements have been applied consistently to all periods presented.

The following standards are issued but not yet effective, and have not been applied to these financial statements. The Company intends to adopt these standards when they become effective. These are not expected to have a material impact on the Company's financial statements:

- IFRS 17: Insurance Contracts; IFRS 17 applies to all types of insurance contracts regardless of the type of entities that issue them, as well as to certain guarantees and financial instruments with discretionary participation features. The standard is currently effective from 1 January 2021 and has not yet been endorsed by the EU. CDC Group plc will assess the expected impact of adopting this standard and it is expected not to have any material impact to the Group.
- Amendments to IFRS 3 Definition of Business.
- Amendments to References to the Conceptual Framework in IFRS Standards.
- Amendments to IAS 1 and IAS 8 Definition of Material.
- Amendments to IFRS 9, IAS 39 and IFRS 7 Interest Rate Benchmark reform.
- Amendments to IAS 1 Classification of liabilities as Current or Non-Current.
- Amendments to IFRS 10 and IAS 28 Sale or Contribution of Assets between an Investor and its Associate or Joint Venture.

17. Changes in accounting policies and disclosures

In 2018, the Company has applied IFRS 9 for the first time.

IFRS 9 'Financial Instruments' replaces IAS 39 'Financial Instruments: Recognition and Measurement'. It makes major changes to the previous guidance on the classification and measurement of financial assets and introduces an 'expected credit loss' model for the impairment of financial assets.

IFRS 9 also contains new requirements on the application of hedge accounting however the Company opts not to apply hedge accounting therefore the new accounting requirements do not impact the Company's financial statements.

The adoption of IFRS 9 has had no impact on the recognition, measurement and classification of the company's financial assets and liabilities.

18. Subsequent events

There have been no material events since the reporting period that would require adjustment to these financial statements. Events after the reporting period that would require adjustment to these financial statements are those that provide evidence of conditions that existed at 31 December 2019. Events after the reporting period that are indicative of conditions that arose after the reporting period do not lead to adjustment of the financial statements, but are disclosed in the event that they are material.

Since 31 December 2019 the Covid-19 pandemic has severely impacted the global economy, including those regions in which the Company invests. The uncertainties over the emergence and spread of Covid-19 have caused market volatility on a global scale. The quantum of the effect on the Company's investments is difficult to determine, however the Company is closely monitoring the situation and considering the effect it may have on the valuation of any impacted investments. The Company is closely monitoring the liquidity needs of its investee companies in order to take action should any emergency funding requirement arise.

In accordance with the requirements of IFRS the fair valuations at the date of the statement of financial position reflect the economic conditions in existence at that date. The next date at which a valuation of investments was performed was as at 31 March 2020. The result a decrease in valuation of US\$11.5M. Any future losses associated with these developments will be recognised in the 2020 financial statements. At present the extent of these potential losses cannot be reliably estimated.